10-year

10-Year Anniversary Promotion (20% off)

Join GuruFocus Premium Membership Now for Only $279/Year

Once a decade discount

Save up to $500 on Global Membership.

Don't Miss It !

Free 7-day Trial
All Articles and Columns »

Weekly Top Insider Buys: MSFT, HPQ, PSX, DG, VRX

June 11, 2012 | About:
gururk

gururk

7 followers
According to GuruFocus Insider Data, these are the largest insider buys during the past week. The overall trend of insiders is illustrated in the chart below:



Microsoft Corp. (MSFT): Director Stephen J. Luczo Bought 17,500 Shares

Director of Microsoft Corp. (MSFT) Stephen J. Luczo bought 17,500 shares on 06/04/2012 at an average price of $29.66. Microsoft develops, manufactures, licenses, and supports a wide range of software products for a multitude of computing devices. Microsoft Corp has a market cap of $249.09 billion; its shares were traded at around $29.66 with a P/E ratio of 10.78 and P/S ratio of 3.56. The dividend yield of Microsoft Corp stocks is 2.7%. Microsoft Corp had an annual average earnings growth of 12.9% over the past 10 years. GuruFocus rated Microsoft Corp the business predictability rank of 4.5-star.

On April 19, company announced quarterly revenue of $17.41 billion for the quarter ended Mar. 31, 2012, a 6% increase from the prior year period. Operating income was $6.37 billion, up 12% from the prior year period.

Recently, other company insiders, such as Chief Accounting Officer Frank H. Brod and Director Bill Gates sold shares of MSFT.

Hewlett Packard (HPQ): Director Ralph V. Whitworth Bought 5,051,265 Shares

Director of Hewlett Packard (HPQ) Ralph V. Whitworth bought 5,051,265 shares on 06/01/2012 at an average price of $22.4. Hewlett Packard is one of the global providers of computing and imaging solutions and services for business and home. Hewlett Packard has a market cap of $44.11 billion; its shares were traded at around $22.4 with a P/E ratio of 5.35 and P/S ratio of 0.35. The dividend yield of Hewlett Packard stocks is 2.15%. Hewlett Packard had an annual average earnings growth of 25.4% over the past 5 years.

On May 23, 2012, company reported quarter net revenue of $30.7 billion, down 3% from the prior-year period and non-GAAP diluted earnings per share of $0.98, above previously provided outlook of $0.88 to $0.91 per shareRecently, Executive Chairman Raymond J. Lane also bought shares of HPQ, but Executive Vice President IPG Vyomesh Joshi sold shares.

Phillips 66 (PSX): Director Marna C. Whittington Bought 2,500 Shares

Director of Phillips 66 (PSX) Marna C. Whittington bought 2,500 shares on 06/05/2012 at an average price of $32.16. Phillips 66 is a downstream energy company. It operates in three segments: Refining & Marketing, Midstream and Chemicals. Phillips 66 has a market cap of $20.08 billion; its shares were traded at around $32.16.

Dollar General (DG): Director William C. Rhodes III Bought 5,000 Shares

Director of Dollar General (DG) William C. Rhodes III bought 5,000 shares on 06/06/2012 at an average price of $50.29. Dollar General Corporation is a discount retailer in the United States. Dollar General has a market cap of $17.02 billion; its shares were traded at around $50.29 with a P/E ratio of 20.12 and P/S ratio of 1.15.

On June 5, 2012, Dollar General Corporation announced the pricing of an underwritten secondary public offering of 30.0 million common shares at a price to the public of$46.75 per share. The shares are being sold by certain existing shareholders. No shares are being sold by the company in this offering, and it will not receive any proceeds from the offering. As part of the deal, Director Adrian M. Jones, 10% Owner Sachs Group Inc. Goldman and 10% Owner Fund KKR Holdings LP sold the company’s shares.

Valeant Pharma (VRX): Director Laurence E. Paul Bought 4,300 Shares

Director of Valeant Pharma (VRX) Laurence E. Paul bought 4,300 shares on 06/01/2012 at an average price of $48.52. Valeant Pharmaceuticals International Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. Valeant Pharma has a market cap of $14.84 billion; its shares were traded at around $48.52 with a P/E ratio of 14.53 and P/S ratio of 6.03.

On May 3, 2012, company announced a total revenue of $856 million and EZSP loss of $0.04. The company updated its guidance for cash EPS for the year to $4.45 to $4.70.

Recently, CFO Howard Bradley Schiller, and Director Laurence E. Paul bought company’s stock.

For the complete list of stocks that bought by their company executives, go to: Insider Buys.
  • CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
  • Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
  • Double Buys:: Companies that both Gurus and Insiders are buying
  • Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.

» Take a Free Trial of Premium Membership


Rating: 2.5/5 (4 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK